Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
FDA Approves Itovebi (inavolisib) for the Combination...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
FDA Approves Cobenfy (xanomeline and trospium...
FDA Grants Traditional Approval to Retevmo...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.